Pharmacotherapy for Smoking Cessation: Present and Future

Author(s): Henri-Jean Aubin, Laurent Karila, Michel Reynaud

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 14 , 2011

Become EABM
Become Reviewer
Call for Editor


Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.

Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [1343 - 1350]
Pages: 8
DOI: 10.2174/138161211796150837
Price: $65

Article Metrics

PDF: 16